Promising data on new B-cell maturation antigen (BCMA)-directed bispecific antibodies were presented at the American Society of Clinical Oncology (ASCO) annual meeting.
These included results on two investigational products: the phase II LINKER-MM1 study, which showed that linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with relapsed/refractory multiple myeloma; and a pooled analysis of the MagnetisMM trials, which revealed that patients with relapsed/refractory multiple myeloma who had already undergone BCMA-directed therapy achieved responses from treatment with elranatamab monotherapy.
MedPage Today brought together three expert leaders in the field: Moderator Sarah A. Holstein, MD, PhD, from the University of Nebraska Medical Center in Omaha, is joined by Brea C. Lipe, MD, from the University of Rochester Medical Center in New York, and Monique Hartley-Brown, MD, from the Dana-Farber Cancer Institute in Boston, for a virtual roundtable discussion. This third of four exclusive episodes on multiple myeloma focuses on treatment with BCMA bispecific antibodies.
…
![The Dopamine Pleasure โ Pain Balance Model for Addiction [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2023/09/mp_165928_0_0jpg.jpg)
![World Lymphoma Awareness [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2023/09/mp_166341_0_0jpg.jpg)
![Blood cancer awareness: Common types, signs and treatment options [Video]](https://crowd-funding.givetaxfree.org/wp-content/uploads/2023/09/mp_167281_0_Cancerpatientjpg.jpg)